PMI Stalingrad
Champigny-sur-Marne, 94500, France
Location status: Recruiting
NCT Number: NCT05815095
This study aims to compare two screening strategies for identifying infants with a potential risk of Autism Spectrum and Neurodevelopmental Disorders to provide early access to care and increase the likelihood of a favorable outcome
Interested in participating?
Request Info3 month–12 month
All sexes
Observational
Champigny-sur-Marne, 94500, France
Location status: Recruiting
This prospective cohort study is performed at several Maternal and Child Protection Services in France. It aims to early detect infants under 12 months of age with a developmental gap compared to that expected for their age.
The first consultation will occur at the same time as the infant's usual medical follow-up at the Maternal and Child Protection Service (usually vaccination in the fourth month and developmental examination at nine months). Two strategies will be evaluated during this visit to assess the infant's neurodevelopmental characteristics. In the first one, a health professional will assess the infant's neurodevelopmental characteristics through routine practice evaluations, such as motor skills, vocalizations, babbling, and social interactions. In the second one, the PREAUT grid will be used for screening of screening for autism spectrum disorder.
Patients with abnormal results in these evaluations would be referred to a specialized center early for advice and treatment if necessary. We will consider an early referral as the referral of infants to an adapted consultation within the month following the first consultation. Also, these patients will be assessed using the State-Trait Anxiety Inventory-Form Y and T and the QUALIN score.
After 12 months of follow-up, data regarding the received treatments of patients who were addressed to a specialized center will be performed.
At 24 and 36 months of follow-up, all the included patients will be assessed with the Modified Checklist for Autism in Toddlers, Revised with Follow-up instrument (M-CHAT-R/F) ,and the IDE ( the French version of the Child Development Inventory). In case of an abnormal result of the M-CHAT-R/F, the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS) will be administered. In case of an abnormal result of the IDE, the Brunet-Lézine scale will be administered.
Finally, the French health insurance claims databases will be used to evaluate the care pathway of all included patients up to 48 months of the child.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
in
Exclusion criteria
Patient with abnormal results in this evaluation would be referred to a specialized center early for advice and treatment if necessary
Time frame: At 2 years of age
Time frame: At 2 and 3 years of age
Time frame: At 2 and 3 years of age
Time frame: At 2 and 3 years of age of child's referral to the Medical psychological center
Time frame: At inclusion in Maternal and Child Protection Services or at Medical-psychological center and at 2 and 3 years of age
Time frame: At a Medical-psychological center and at 2 and 3 years of age
Time frame: At 2 and 3 years of age
Time frame: Through study completion, an average of 4 years
Time frame: Through study completion, an average of 4 years
Time frame: Through study completion, an average of 4 years
Time frame: Through study completion, an average of 4 years
Time frame: At the inclusion, at the end of inclusion and at the late visit
Time frame: At 4 years of the child
Contact information is provided by the study sponsor or research team.
Camille JUNG, MD
CONTACT
Catherine DELMAS, MD
CONTACT
Centre Hospitalier Intercommunal Creteil
Other
Randomized Pragmatic, Cluster, Stepped-wedge Trial of Early Detection and Referral for Autism and Neurodevelopmental Disorders at the Maternal and Child Protection Services for Care Before 1 Year of Follow-up
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06081348
22Q11 Deletion, 22q11 Deletion Syndrome
Calgary, Alberta, Canada
View Trial DetailsNCT04096430
Autism Spectrum Disorder, Brain Damage, Chronic
Calgary, Alberta, Canada
View Trial DetailsNCT05681923
Autism Spectrum Disorder, Child Development Disorders, Pervasive
Montpellier, France
View Trial DetailsNCT07439276
Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder
Paris, France
View Trial Details